SKU: P007  / 
    CAS Number: 1405-20-5

    Polymyxin B Sulfate, USP

    $117.50 - $459.30

    Polymyxin B Sulfate, USP is a polypeptide antibiotic mixture composed of Polymyxins B1, B2, and B3 fractions, with B1 and B2 fractions comprising the majority of the mixture. Polymyxin B components are structurally identical with the exception of a variable fatty acid group on each fraction. Results from in vitro studies have shown marginal differences in MIC data when comparing the fractions. Polymyxin B Sulfate is freely soluble in aqueous solution (25 mg/mL).

    Polymyxin B Sulfate, USP conforms to United States Pharmacopoeia specifications.

    We also offer:

    • Polymyxin B1 Sulfate, EvoPure® (P037)
    • Polymyxin B1-I Sulfate, EvoPure® (P038)
    • Polymyxin B2 Sulfate, EvoPure® (P039)
    • Polymyxin B3 Sulfate, EvoPure® (P040)
    • Polymyxin B6 Sulfate, EvoPure® (P054)
    • Polymyxin E1 Sulfate, EvoPure® (P055)
    • Polymyxin E2 Sulfate, EvoPure® (P056)

    EvoPure® products are purified single antibiotic fractions, most are >99% pure. Highly pure EvoPure® Polymyxin products can be used to analyze the specifc effects of individual Polymyxin B fractions.

    Mechanism of Action Polymyxin B targets and alters the permeability of lipopolysaccharide (LPS) found in Gram-negative bacteria leading to lysing of the cell. Polymyxin B only needs to interact with LPS, it is not required to enter the cell.
    Spectrum Polymyxin B Sulfate targets the outer membrane of Gram-negative bacteria especially Pseudomonas aeruginosa.
    Impurity Profile Polymyxin B1||4135-11-9|C56H98N16O13|1204| Polymyxin B2|||C55H96N16O13|1190| Polymyxin B3|||C55H96N16O13|1190| Polymyxin B1-I|||C56H98N16O13|1204|
    Microbiology Applications Polymyxin B Sulfate is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-negative microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options.  Representative MIC values include:
    • Pseudomonas aeruginosa 0.25 µg/mL – 1 µg/mL
    • For a representative list of Polymyxin B Sulfate MIC values, click here.

    Media Supplements:

    Polymyxin B is routinely used as a selection agent in several types of isolation media:

    Perfringens agar - Supplement A and Supplement B

    Perfringens Agar - SFP and TSC Selective Supplements

    Columbia Blood AgarCampylobacter Selective Supplement (Skirrow)

    Columbia Blood Agar - Campylobacter Selective Supplement (Blaser-Wang)

    Brucella mediumBrucella Selective Supplement

    MYP Agar - Polymyxin B Bacillus Selection Supplement

    Legionella CYE Agar - Legionella BMPA-α Selective Supplement

    Legionella CYE Agar - Legionella MWY Selective Supplement

    Campylobacter Agar - Campylobacter Selective Supplement (Preston)

    PALCAM Agar - PALCAM Selective Supplement

    Legionella CYE Agar - Legionella GVPC Selective Supplement

    m-CP Medium - Membrane C. perfringens Selective Supplement

    Burkholderia cepacia Agar Base - Burkholderia cepacia Selective Supplement

    ORSAB - ORSAB Selective Supplement

    Campylobacter Agar Base - Modified Preston Campylobacter Selective Supplement

    Brucella Medium Base - Modified Brucella Selective Supplement

    Legionella CYE Agar - Legionella GVPN Selective Supplement

    ChromogenicListeria Agar - Chromogenic Listeria Selective Supplement

    ChromogenicBacillus cereus Agar - Chromogenic Bacillus cereus Selective Supplement

    ChromogenicListeria Agar - Chromogenic Listeria Differential Supplement

    Plant Biology Applications Polymyxin B Sulfate was successfully tested to counteract phytopathogenic Gram-negative bacterial growth including different strains of Pseudomonas viridiflava and Erwinia carotovora. Polymixin B Sulfate was shown to reduce bacterial growth of different strains of Pseudomonas viridiflava at low concentrations, (0.08 µg/ml) and Erwinia carotovora growth at slightly higher concentrations (0.25 µg/ml) (Selim et al. 2005). Polymyxin B has been shown to elict alkaloid accumulation in E. californica. Treatment at 0.04 mg/ml for 4 hours showed a 5.5x increase in Jasmonate levels.
    References

    Kassamali et al used Polymyxin B1Polymyxin B2Polymyxin B3, and Polymyxin B1-I (TOKU-E) to test for synergistic and antagonistic effects against various Gram-negative organisms in:  "Microbiological assessment of Polymyxin B components tested alone and in combination"

    Lim et al used Polymyxin B1, B2, B3, and B1-I (TOKU-E) to study the stability of each compound in saline, dextrose, and saline/dextrose infusion solutions in: "Physicochemical stability study of Polymyxin B in various infusion solutions for administration to critically ill patients."

    Cao G et al (2009)  Development and validation of a reversed-phase high-performance liquid chromatography assay for Polymyxin B in human plasma. J. Antimicrob. Chemother.  62(5):1009-1014 PMID 18765414

    Mueller MJ, Brodschelm W, Spannagl E and Zenk MH (1993)  Signaling in the elicitation process is mediated through the octadecanoid pathway leading to jasmonic acid.  Proc. Natl. Acad. Sci. USA 90(16):7490-7494  PMID 11607420

    Newton BA (1956)  The properties and mode of action of the Polymyxins. Bacter. Rev.  20(1):14-27  PMID 13303920

    Orwa JA et al (2001)  Isolation and structural characterization of Polymyxin B components. J Chromatogr A 912(2):369-373  PMID 11330807

    Selim S, Negrel J, Govaerts C, Gianinazzi S and Tuinen van D (2005)  Isolation and partial characterization of antagonistic peptides produced by Paenibacillus sp. strain B2 isolated from the sorghum Mycorrhizosphere. Appl. Environ. Microbiol. 71(11):6501–6507  PMID 16269674

    Zavascki AP, Goldani LA, Li J and Nation RL (2007)  Polymyxin B for the treatment of multidrug-resistant pathogens: A critical review. J. Antimicrob. Chemother.  60(6):1206-1215  PMID 17878146

    Tam VH, Cao H, Ledesma, KR, Hu M (2011)  In vitro potency of various Polymyxin B components.55(9):4490-491  PMID 21709096

     

     

    MIC Diplococcus pneumoniae| ≥400|| Fusobacterium necrophorum| 8.1 - 100|| Haemophilus influenzae| ≥0.8|| Pseudomonas aeruginosa| 0.25 - 1||